Enhancing Endovascular Procedures for Improved Clinical Outcomes.

Arch Protection System

Clinical evidence is emerging that suggests an increased risk of stroke is associated with emerging therapies such as trans-aortic valve implantation (TAVI). Lumen believes its platform technology has the ability to offer novel solutions to potentially improve patient outcomes for this and similar procedures.

Learn More about Arch Protection System

Ischemic Stroke System

Stroke is the third leading cause of death and the leading cause of disability in the United States. Lumen believes its platform technology can be applied to develop a novel device designed to revascularize or open up a blood vessel that is blocked by a blood clot.

Learn More about Ischemic Stroke System

June 28, 2011

Medtronic purchases the FiberNet Embolic Protection product line from Lumen Biomedical Inc

February 8, 2010

Volcano announces purchase of Xtract Product

Learn More

January 12, 2010

Completion of FORTRESS clinical study

Learn More

May 18, 2009

Volcano Announces Worldwide Exclusive Distribution Agreement With Lumen Biomedical for Xtract(TM) Thrombus Aspiration Catheter

Learn More

January 29, 2009

Invatec Announces Worldwide Distribution Agreement with Lumen Biomedical

Learn More

November 19, 2008

FDA Approves Lumen Biomedical's FiberNet Embolic Protection System for Carotid Artery Stenting

Learn More

October 22, 2008

Lumen Biomedical Receives FDA Clearance of Embolectomy System for Treatment of Peripheral Artery Disease

Learn More

Past Press Releases